Trials / Completed
CompletedNCT02578030
Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD
A Phase 1, Open-label Study of the Pharmacokinetics of d- and L-amphetamine After a Single Dose of SHP465 12.5 mg or 25 mg Administered to Children and Adolescents Aged 6 to17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
To provide additional, required information on the pharmacokinetic profile of SHP465 in the targeted population (children and adolescents aged 6-17 years of age with ADHD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHP465 12.5mg | |
| DRUG | SHP465 25mg |
Timeline
- Start date
- 2015-10-24
- Primary completion
- 2015-11-10
- Completion
- 2015-11-10
- First posted
- 2015-10-16
- Last updated
- 2021-05-18
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02578030. Inclusion in this directory is not an endorsement.